| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(12)62177-1 |
| P8608 | Fatcat ID | release_xgdl6klfyre75ml24ve6crj4e4 |
| P698 | PubMed publication ID | 23415013 |
| P2093 | author name string | Freek W A Verheugt | |
| Johannes C Kelder | |||
| Jurriën M ten Berg | |||
| Tom Adriaenssens | |||
| Marije M Vis | |||
| Mathias Vrolix | |||
| Jean-Paul Herrman | |||
| Willem J M Dewilde | |||
| Arnoud W van 't Hof | |||
| Antonius A C M Heestermans | |||
| Bart J G L De Smet | |||
| Jan G P Tijsen | |||
| Tom Oirbans | |||
| WOEST study investigators | |||
| P2860 | cites work | Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 |
| Managing the anticoagulated patient with atrial fibrillation at high risk of stroke who needs coronary intervention | Q47348329 | ||
| Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective | Q50188024 | ||
| Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. | Q54135542 | ||
| ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article | Q56986819 | ||
| Bleeding risk assessment and management in atrial fibrillation patients | Q57627129 | ||
| Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting | Q57627371 | ||
| Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody | Q79804186 | ||
| ??? | Q28255148 | ||
| Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction | Q22242900 | ||
| Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial | Q26248603 | ||
| Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation | Q28167576 | ||
| Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting | Q28183958 | ||
| Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial | Q28193437 | ||
| Warfarin, aspirin, or both after myocardial infarction | Q28193836 | ||
| Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting | Q28218635 | ||
| An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators | Q28254763 | ||
| Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 | ||
| A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. | Q33504515 | ||
| Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial | Q34134664 | ||
| Clinical end points in coronary stent trials: a case for standardized definitions | Q36807166 | ||
| Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis | Q37092388 | ||
| ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: A Report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Societ | Q37365044 | ||
| Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice | Q37499351 | ||
| Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium | Q37889006 | ||
| Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. | Q38005781 | ||
| Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance | Q38373039 | ||
| Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial | Q38474249 | ||
| Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study | Q38479317 | ||
| Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). | Q39479800 | ||
| Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology | Q39734057 | ||
| Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST). | Q42637505 | ||
| Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation | Q42908804 | ||
| Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). | Q42923039 | ||
| Duration of dual antiplatelet therapy after implantation of drug-eluting stents. | Q43128835 | ||
| Three-year survival following multivessel percutaneous coronary intervention with bare-metal or drug-eluting stents in unselected patients | Q44438496 | ||
| Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. | Q46209759 | ||
| P433 | issue | 9872 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspirin | Q18216 |
| clopidogrel | Q410237 | ||
| anticoagulant | Q215118 | ||
| anticoagulation | Q63279445 | ||
| P304 | page(s) | 1107-1115 | |
| P577 | publication date | 2013-02-13 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial | |
| P478 | volume | 381 |
| Q22241922 | 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines |
| Q27341873 | 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society |
| Q37647504 | 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: comments from the Dutch ACS working group |
| Q57621041 | 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS |
| Q50089557 | 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. |
| Q50196541 | 2017 ESC/EACTS Guidelines for the management of valvular heart disease |
| Q58550785 | 2018 Korean Guideline of Atrial Fibrillation Management |
| Q90397090 | A Brave New World |
| Q38631166 | A retrospective study on the risk factors for bleeding events in warfarin therapy, focusing on renal function |
| Q57764209 | ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome |
| Q88960063 | Acute coronary syndromes |
| Q30248576 | Acute myocardial infarction |
| Q50101365 | Acute myocardial infarction in patients with ST-segment elevation myocardial infarction : ESC guidelines 2017 |
| Q36087396 | Acute myocardial infarction in the elderly |
| Q37291843 | Acute right ventricular failure caused by concomitant coronary and pulmonary embolism: successful treatment with endovascular coronary and pulmonary thrombectomy |
| Q40884884 | Adverse cardiovascular events in acute coronary syndrome with indications for anticoagulation. |
| Q38697344 | Age is not a bar to PCI: Insights from the long-term outcomes from off-site PCI in a real-world setting |
| Q60923308 | Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy |
| Q93149636 | Anti-thrombotic therapy strategies with long-term anticoagulation after percutaneous coronary intervention - a systematic review and meta-analysis |
| Q38952931 | Anticoagulant and Antiplatelet Prescribing Patterns for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention. |
| Q52325500 | Anticoagulation Management After Transcatheter and Surgical Valve Replacement. |
| Q47984703 | Anticoagulation after coronary stenting: a systemic review |
| Q47800627 | Anticoagulation combined with antiplatelet therapy in patients with left ventricular thrombus after first acute myocardial infarction |
| Q89821468 | Anticoagulation in Patients with Atrial Fibrillation and Coronary Artery Disease |
| Q47581328 | Anticoagulation in atrial fibrillation : Current evidence and guideline recommendations |
| Q49502957 | Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy? |
| Q89220120 | Antiplatelet Agents in Secondary Stroke Prevention: Selection, Timing, and Dose |
| Q33740815 | Antiplatelet Therapy Combinations and Thrombogenicity in Patients with Non-Valvular Atrial Fibrillation. |
| Q38535999 | Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation |
| Q52593614 | Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma. |
| Q93379484 | Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare |
| Q38106501 | Antiplatelet and anticoagulant strategies in acute coronary syndrome: where we are in 2013. |
| Q26824701 | Antiplatelet and anticoagulation therapy for acute coronary syndromes |
| Q48761201 | Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease |
| Q38995602 | Antiplatelet therapies in patients with an indication for anticoagulation |
| Q57914526 | Antiplatelet therapy and anticoagulants |
| Q87051631 | Antiplatelet therapy and anticoagulants |
| Q46192628 | Antiplatelet therapy and anticoagulants - authors' reply |
| Q38570608 | Antiplatelet therapy in acute coronary syndromes |
| Q39322781 | Antiplatelet therapy strategies after percutaneous coronary intervention in patients needing oral anticoagulation |
| Q38384163 | Antiplatelet treatment in essential hypertension: where do we stand? |
| Q60957668 | Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation: Korean National Health Insurance Service National Cohort |
| Q35627390 | Antithrombotic Regimens for Patients Taking Oral Anticoagulation After Coronary Intervention: A Meta-analysis of 16 Clinical Trials and 9,185 Patients |
| Q59795416 | Antithrombotic Regimens in Patients With Percutaneous Coronary Intervention Whom an Anticoagulant Is Indicated: A Systematic Review and Network Meta-Analysis |
| Q98613603 | Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention |
| Q90380295 | Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy |
| Q28072522 | Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation |
| Q39295736 | Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention |
| Q58751103 | Antithrombotic therapies for elderly patients: handling problems originating from their comorbidities |
| Q37517942 | Antithrombotic therapy - predictor of early and long-term bleeding complications after transcatheter aortic valve implantation |
| Q50068546 | Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention |
| Q38541932 | Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulant treatment. A meta-analysis |
| Q30886769 | Antithrombotic therapy and outcomes after ICD implantation in patients with atrial fibrillation and coronary artery disease: an analysis from the National Cardiovascular Data Registry (NCDR)®. |
| Q35111496 | Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients |
| Q38108234 | Antithrombotic therapy for patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention: a review |
| Q97418297 | Antithrombotic therapy in coronary artery disease patients with atrial fibrillation |
| Q35161633 | Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study. |
| Q87096599 | Antithrombotic therapy in patients undergoing TAVI with concurrent atrial fibrillation. One center experience |
| Q37668130 | Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals |
| Q92425851 | Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease |
| Q52804575 | Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials? |
| Q38545163 | Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. |
| Q46249138 | Antithrombotic therapy strategies for atrial fibrillation patients undergoing percutaneous coronary intervention: A systematic review and network meta-analysis |
| Q38232135 | Antithrombotics in atrial fibrillation and coronary disease |
| Q89539076 | Apixaban: An Update of the Evidence for Its Place in the Prevention of Stroke in Patients with Atrial Fibrillation |
| Q55380343 | Arrhythmias in Patients ≥80 Years of Age: Pathophysiology, Management, and Outcomes. |
| Q89423195 | Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention |
| Q92103551 | Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events |
| Q91136259 | Atrial fibrillation-related stroke in women: Evidence and inequalities in epidemiology, mechanisms, clinical presentation, and management |
| Q33359459 | Atrial fibrillation: state of the art. |
| Q94063670 | Author`s Reply |
| Q33936118 | Balancing antiplatelet and anticoagulant therapies in patients with cardiovascular disease |
| Q37561924 | Balancing between bleeding and thromboembolism after percutaneous coronary intervention in patients with atrial fibrillation. Could triple anticoagulant therapy be a solution? |
| Q38264835 | Balancing ischaemia and bleeding risks with novel oral anticoagulants |
| Q39121292 | Bleeding complication of triple therapy of rivaroxaban, prasugrel, and aspirin: a case report and general discussion |
| Q51319005 | Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. |
| Q46465498 | Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents |
| Q38244795 | Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. |
| Q58091219 | Causes and predictors of early readmission after percutaneous coronary intervention among patients discharged on oral anticoagulant therapy |
| Q36429754 | Clinical Relevance of Anticoagulation and Dual Antiplatelet Therapy to the Outcomes of Patients With Atrial Fibrillation and Recent Percutaneous Coronary Intervention With Stent |
| Q51736773 | Clinical effects with inhibition of multiple coagulative pathways in patients admitted for acute coronary syndrome. |
| Q38380465 | Clinical evidence for oral antiplatelet therapy in acute coronary syndromes |
| Q38307535 | Clinical pharmacokinetics and pharmacodynamics of clopidogrel |
| Q33750028 | Clinical review: bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and management |
| Q27000967 | Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation - patient considerations |
| Q47691483 | Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial |
| Q93227275 | Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial |
| Q38153606 | Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard? |
| Q45139344 | Combined anticoagulation and antiplatelet therapy in AF patients: why do we not follow guidelines? |
| Q38963690 | Combined aspirin and anticoagulant therapy in patients with atrial fibrillation. |
| Q53655058 | Combined use of warfarin and oral P2Y12 inhibitors in patients with atrial fibrillation and acute coronary syndrome. |
| Q58805896 | Combining anticoagulation and antiplatelet drugs in coronary artery disease |
| Q87871432 | Combining oral anticoagulation and antiplatelet therapies: appropriate patient selection |
| Q38165916 | Commentary on late breaking trials in interventional cardiology at ESC, VIVA, TCT, AHA (Fall 2012), and ACC 2013. |
| Q90397085 | Comparative Effectiveness and Safety of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome or Percutaneous Coronary Intervention |
| Q55618390 | Comparison of Systematic Ticagrelor-Based Dual Antiplatelet Therapy to Selective Triple Antithrombotic Therapy for Left Ventricle Dysfunction Following Anterior STEMI. |
| Q39677417 | Comparison of mid-term outcomes between patients with and without atrial fibrillation undergoing coronary stenting in the second-generation drug-eluting stent era: from the SHINANO registry. |
| Q28078445 | Complementary role of cardiac CT in the assessment of aortic valve replacement dysfunction |
| Q49936547 | Concomitant Use of Antiplatelets and Anticoagulants in Patients with Coronary Heart Disease and Atrial Fibrillation: What Do Recent Clinical Trials Teach Us? |
| Q36713982 | Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial |
| Q34174001 | Concurrent pulmonary thrombosis with systemic embolism: a case report |
| Q56384060 | Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease |
| Q30251866 | Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs |
| Q88195606 | Contemporary Antiplatelet Strategies in the Treatment of STEMI using Primary Percutaneous Coronary Intervention |
| Q38793797 | Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease |
| Q48639751 | Contemporary Use of Oral Antithrombotic Agents: Focus on Dual and Triple Therapeutic Approaches |
| Q38186094 | Contemporary anticoagulation therapy in patients undergoing percutaneous intervention |
| Q46663237 | Controversies regarding the new oral anticoagulants for stroke prevention in patients with atrial fibrillation |
| Q38689160 | Coronary revascularisation in older patients with non-ST elevation acute coronary syndromes. |
| Q64118635 | Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial |
| Q38628836 | Deciding on a combination of anticoagulant and antiplatelet drugs |
| Q92211505 | Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention |
| Q92214029 | Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk |
| Q37412869 | Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fi |
| Q64974187 | Development of New Antithrombotic Regimens for Patients with Acute Coronary Syndrome. |
| Q101213365 | Differential Effects of Clopidogrel with or without Aspirin on Platelet Reactivity and Coagulation Activation: a randomized trial in healthy volunteers |
| Q50207168 | Direct oral anticoagulant and antiplatelet combination therapy: Hemorrhagic events in coronary artery stent recipients |
| Q90299348 | Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis |
| Q64063873 | Double Jeopardy: Will the new trials tell us how to manage patients with atrial fibrillation and coronary artery disease? |
| Q90319728 | Double or Triple Antithrombotic Treatment in Atrial Fibrillation Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention |
| Q26741058 | Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel |
| Q92553383 | Drug-eluting versus bare-metal stents for first myocardial infarction in patients with atrial fibrillation: A nationwide population-based cohort study |
| Q39383567 | Dual Antiplatelet Therapy Beyond One Year in Patients After Stent Placement: A Review |
| Q93198626 | Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues |
| Q52597322 | Dual Antithrombotic Therapy with Clopidogrel and Novel Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Real-world Study. |
| Q36058292 | Dual antiplatelet compared to triple antithrombotic therapy in anterior wall acute myocardial infarction complicated by depressed left ventricular ejection fraction |
| Q52813379 | Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS : Redefining the optimal duration of treatment. |
| Q42650020 | Dual antiplatelet therapy for secondary prevention of coronary artery disease. |
| Q38261199 | Dual antiplatelet therapy in the anticoagulated patient undergoing percutaneous coronary intervention risks, benefits, and unanswered questions |
| Q38217152 | Dual antiplatelet therapy with or without oral anticoagulation in the postdischarge management of acute coronary syndrome patients with an indication for long term anticoagulation: a systematic review |
| Q38563586 | Dual antiplatelet therapy, drug-eluting stents and bioresorbable vascular scaffolds: Evolutionary perspectives |
| Q46201161 | Dual or single antiplatelet therapy with anticoagulation? |
| Q30252011 | Dual pathway therapy in acute coronary syndrome |
| Q55303947 | Dual versus single antiplatelet therapy for patients with long-term oral anticoagulation undergoing coronary intervention: a systematic review and meta-analysis. |
| Q92740877 | Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease |
| Q50868321 | Duration of dual anti-platelet therapy following drug eluting stents: Less Is More? |
| Q42333630 | Duration of triple antithrombotic therapy and outcomes among patients undergoing percutaneous coronary intervention |
| Q90074563 | Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q28552288 | Early Clinical Experience with a Polymer-Free Biolimus A9 Drug-Coated Stent in DES-Type Patients Who Are Poor Candidates for Prolonged Dual Anti-Platelet Therapy |
| Q45330939 | Early coronary vein stenosis after cardiac resynchronization therapy. |
| Q91640052 | Editorial to the "safety and efficacy of direct oral anticoagulants compared to vitamin K antagonist post percutaneous coronary artery interventions in patients with atrial fibrillation: A systematic revie and meta-analysis" |
| Q40848030 | Effect of Shenzhu Guanxin Recipe () on patients with angina pectoris after percutaneous coronary intervention: A prospective, randomized controlled trial |
| Q38409730 | Effective practical management of patients with atrial fibrillation when using new oral anticoagulants |
| Q40215137 | Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects. |
| Q92121403 | Efficacy and Safety of Antiplatelet Therapy Plus Xa Factor Inhibitors in Patients with Coronary Heart Disease: A Meta-Analysis |
| Q38447545 | Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation |
| Q55404580 | Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis. |
| Q45795390 | Efficacy and safety of triple versus dual antithrombotic therapy in atrial fibrillation and ischemic heart disease: a systematic review and meta-analysis |
| Q26765023 | Emerging Tools for Stroke Prevention in Atrial Fibrillation |
| Q36068352 | Emerging roles of thioredoxin cycle enzymes in the central nervous system |
| Q36771378 | Engaging with quality improvement in anticoagulation management |
| Q30252099 | Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies |
| Q43487404 | Evolving antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: results from a survey among US cardiologists. |
| Q38635568 | Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon? |
| Q91787892 | Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting |
| Q50085963 | Focused update on dual antiplatelet treatment : ESC guidelines 2017 |
| Q92098157 | For Patients Needing Oral Anticoagulation for Atrial Fibrillation and Dual Antiplatelet Therapy after Percutaneous Coronary Intervention, Is Double Therapy Preferred over Triple Therapy? |
| Q22306331 | Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association |
| Q52806304 | Heart-breaking aspirin interruption. |
| Q38844348 | High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting |
| Q38969861 | Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies |
| Q92456065 | Impact of Baseline Anemia in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A Prespecified Analysis From the VALIDATE-SWEDEHEART Trial |
| Q35851558 | Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials). |
| Q42690175 | Impact of Paclitaxel-Eluting Balloons Compared to Second-Generation Drug-Eluting Stents for of In-Stent Restenosis in a Primarily Acute Coronary Syndrome Population |
| Q35903857 | Impact of Triple Therapy in Elderly Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention |
| Q38169058 | Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes. |
| Q33679528 | Impact of platelet transfusion on survival of patients with intracerebral hemorrhage after administration of anti-platelet agents at a tertiary emergency center |
| Q47555409 | Impact of triple antithrombotic therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention in real-world practice |
| Q26766094 | Improved Cardiovascular Disease Outcomes in Older Adults |
| Q94570689 | Improving outcomes of percutaneous coronary interventions in patients with stable ischemic heart disease |
| Q49386697 | In vitro inhibition of platelets aggregation with generic form of clopidogrel versus branded in patients with stable angina pectoris |
| Q36225513 | Incidence and Predictors of Left Ventricular Thrombus After Primary Percutaneous Coronary Intervention for Anterior ST-Segment Elevation Myocardial Infarction |
| Q38480637 | Intensive care unit management of transcatheter aortic valve recipients |
| Q46251320 | Interventional cardiology: Antithrombotic therapy for PCI--getting the balance right |
| Q38132255 | Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation |
| Q90055276 | Is dual therapy the correct strategy in frail elderly patients with atrial fibrillation and acute coronary syndrome? |
| Q41111702 | Is it possible to perform gastric endoscopic submucosal dissection without discontinuation of a single antiplatelet of thienopyridine derivatives? |
| Q37497560 | Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial |
| Q54488050 | Japanese postmarketing surveillance of clopidogrel for patients with non-ST-segment-elevation acute coronary syndrome indicated for percutaneous coronary intervention (J-PLACE NSTE-ACS). |
| Q89563788 | LMU Munich: platelet inhibition novel aspects on platelet inhibition and function |
| Q47328033 | Left Atrial Appendage Closure with Amplatzer Cardiac Plug in Nonvalvular Atrial Fibrillation: Safety and Long-Term Outcome |
| Q96304369 | Long-term monotherapy with ticagrelor after coronary stenting: the GLOBAL LEADERS study |
| Q86958630 | Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents |
| Q90288202 | Looking into the next decade of antithrombotic therapy for patients with atrial fibrillation and percutaneous coronary intervention |
| Q41069868 | Low On-Treatment Platelet Reactivity Predicts Long-Term Risk of Bleeding After Elective PCI. |
| Q39026788 | Management of Atrial Fibrillation in Elderly Adults |
| Q90122743 | Management of Left Ventricular Thrombi with Direct Oral Anticoagulants: Retrospective Comparative Study with Vitamin K Antagonists |
| Q38975409 | Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association |
| Q50727728 | Management of acute coronary syndrome in patients with non-valvular atrial fibrillation: results of the European Heart Rhythm Association Survey. |
| Q40478828 | Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. |
| Q38364982 | Management of antithrombotic therapy in patients undergoing electrophysiological device surgery |
| Q38369003 | Management of atrial fibrillation: What is new in the 2014 ACC/AHA/HRS guideline? |
| Q35991815 | Management of the patient with an acute coronary syndrome using oral anticoagulation |
| Q28080247 | Managing Antiplatelet Therapy and Anticoagulants in Patients with Coronary Artery Disease and Atrial Fibrillation |
| Q26775877 | Managing atrial fibrillation in the very elderly patient: challenges and solutions |
| Q88195712 | Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulation |
| Q38664074 | Meta-Analysis of Oral Anticoagulants with Dual versus Single Antiplatelet Therapy in Patients after Percutaneous Coronary Intervention |
| Q49360165 | Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban, Dabigatran) in Patients With Acute Coronary Syndrome. |
| Q47709533 | More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions |
| Q38238950 | New advances in the treatment of atrial fibrillation: focus on stroke prevention |
| Q37304566 | New antiplatelet agents for cardiovascular disease |
| Q41961248 | New oral anticoagulants - will they be used with antiplatelet drugs in patients with atrial fibrillation after acute coronary syndrome? |
| Q37593158 | New oral anticoagulants: are coagulation units still required? |
| Q53256913 | New scoring model (DARSYM score) to predict post-discharge bleeding after successful second-generation drug-eluting stent implantation. |
| Q90277215 | New-Onset Atrial Fibrillation in St-Segment Elevation Myocardial Infarction: Predictors and Impact on Therapy And Mortality |
| Q94230261 | Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis |
| Q38257119 | Novel antiplatelet agents in acute coronary syndrome |
| Q38153782 | Novel approaches for prevention of stroke related to transcatheter aortic valve implantation |
| Q57179203 | Novel aspects of antiplatelet therapy in cardiovascular disease |
| Q38101845 | Novel oral anticoagulants: clinical pharmacology, indications and practical considerations |
| Q38437086 | One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry |
| Q89891542 | Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis |
| Q55260829 | Optimal antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention: triple therapy is too much! |
| Q38176288 | Optimizing antithrombotic therapy after coronary stent implantation in patients on chronic oral anticoagulation |
| Q55105393 | Optimum Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation and Undergoing Percutaneous Coronary Intervention. |
| Q58781692 | Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios |
| Q38380476 | Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs |
| Q47336250 | Oral anticoagulation therapy upon discharge in hospitalized patients with nonvalvular atrial fibrillation: a retrospective cohort study. |
| Q47304863 | Outcome of octogenarians with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. |
| Q41627417 | Outcomes and Prognostic Impact of Prophylactic Oral Anticoagulation in Anterior ST-Segment Elevation Myocardial Infarction Patients With Left Ventricular Dysfunction |
| Q40257227 | Outcomes following implantation of the Biolimus A9-eluting BioMatrix coronary stent: Primary analysis of the e-BioMatrix registry |
| Q89601115 | P2Y12 inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis |
| Q38626782 | Pathophysiology of ST-segment elevation myocardial infarction: novel mechanisms and treatments. |
| Q44714275 | Patient selection for the implantation of a left atrial appendage occluder in primary and secondary prevention of cardioembolic stroke in atrial fibrillation |
| Q88195597 | Percutaneous Coronary Intervention in Patients Who Have an Indication for Oral Anticoagulation - an Evidence-based Approach to Antithrombotic Therapy |
| Q39002814 | Percutaneous Coronary Intervention of Complex Calcified Lesions With Drug-Coated Balloon After Rotational Atherectomy |
| Q38244025 | Percutaneous coronary intervention and atrial fibrillation: the triple therapy dilemma |
| Q50435881 | Percutaneous coronary intervention for three vessels of chronic total occlusion complicated with huge left ventricular thrombus |
| Q93055882 | Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study |
| Q26862694 | Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments |
| Q38229559 | Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper |
| Q50014351 | Platelet inhibition in patients with coronary, cerebral and peripheral macroangiopathy : What, when and how long? |
| Q41968141 | Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study |
| Q58792339 | Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis |
| Q38433830 | Post-PCI Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation |
| Q37040299 | Postdischarge Bleeding After Percutaneous Coronary Intervention and Subsequent Mortality and Myocardial Infarction: Insights From the HMO Research Network-Stent Registry |
| Q57154436 | Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations |
| Q54580380 | Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial. |
| Q53249162 | Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey. |
| Q91800605 | Prevalence of drug-drug interaction in atrial fibrillation patients based on a large claims data |
| Q26801820 | Preventing bleeding and thromboembolic complications in atrial fibrillation patients undergoing surgery |
| Q46549519 | Prevention of Bleeding in Patients With Atrial Fibrillation Undergoing PCI (PIONEER): Three May End Up Being a Crowd. |
| Q92896971 | Previous Antithrombotic Therapy, Particularly Anticoagulant, Is Associated with Unfavorable Outcomes in Patients with Primary Spontaneous Intracerebral Hemorrhage Receiving Craniotomy: A Nationwide Population-Based Cohort Study |
| Q87081666 | Primary PCI in dabigatran-treated patient: is transradial approach and bivalirudin infusion a safe and effective therapeutic option? |
| Q44282782 | Primary percutaneous coronary intervention and bleeding risk in the era of drug-eluting stent: a long-term cohort study. |
| Q41073197 | Primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction in a patient taking dabigatran for chronic anticoagulation |
| Q49687467 | Prognostic Value of Ankle-Brachial Index in Patients Undergoing Percutaneous Coronary Intervention: In-Hospital and 1-Year Outcomes From the SHINANO Registry |
| Q35821319 | Proteins interacting with the 26S proteasome |
| Q57462908 | Radiofrequency catheter ablation prior to percutaneous coronary intervention in patients with atrial fibrillation coexisting with stable coronary artery disease: a single-center pilot study |
| Q94476070 | Rationale and design of a prospective multi-center randomized trial of EARLY treatment by rivaroxaban versus warfarin in ST-segment elevation MYOcardial infarction with Left Ventricular Thrombus (EARLY-MYO-LVT trial) |
| Q88085870 | Real-world antithrombotic therapies and clinical outcomes after second-generation drug-eluting stent implantation in patients with atrial fibrillation: a multi-center cohort study |
| Q35626702 | Recent advances in the diagnosis and treatment of acute myocardial infarction |
| Q26862897 | Recent advances in treatment of acute coronary syndromes |
| Q30544234 | Recurrent intraventricular thrombus six months after ST-elevation myocardial infarction in a diabetic man: a case report |
| Q58110174 | Relationship of Left Ventricular Thrombus Formation and Adverse Outcomes in Acute Anterior Myocardial Infarction in Patients Treated with Primary Percutaneous Coronary Intervention |
| Q37390016 | Resolution of left ventricular postinfarction thrombi in patients undergoing percutaneous coronary intervention using rivaroxaban in addition to dual antiplatelet therapy. |
| Q38201161 | Revascularization strategies for patients with stable coronary artery disease. |
| Q26776254 | Review of the top 5 cardiology studies of 2013-14 |
| Q39273301 | Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies |
| Q58715507 | Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study |
| Q38398587 | Risks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary intervention |
| Q26825230 | Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice |
| Q38188899 | Rivaroxaban: a review of its use in acute coronary syndromes |
| Q38171396 | Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes |
| Q37461045 | STENTING STRATEGY AND FOLLOW-UP RESULTS OF MULTI-CENTER REGISTRY IN FUKUSHIMA CITY FOR LEFT MAIN CORONARY ARTERY DISEASE: BARE METAL STENT VERSUS DRUG-ELUTING STENT. |
| Q55113397 | Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. |
| Q51760655 | Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site andSystemic Implementation of AngioX (MATRIX) trial. |
| Q38173148 | Secondary stroke prevention |
| Q53076603 | Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation. |
| Q37681956 | Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs |
| Q53405663 | Solving the Issue of Restenosis After Stenting of Intracranial Stenoses: Experience with Two Thin-Strut Drug-Eluting Stents (DES)-Taxus Element™ and Resolute Integrity™. |
| Q92612170 | Statement on Antiplatelet Agents and Anticoagulants in Cardiology - 2019 |
| Q92605110 | Status of international normalized ratio control and treatment patterns in patients with nonvalvular atrial fibrillation taking vitamin K antagonist with or without antiplatelet therapy: Results from KORAFII registry |
| Q26785321 | Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014 |
| Q38217692 | Strategies to reduce bleeding risk in acute coronary syndromes and percutaneous coronary intervention: new and emerging pharmacotherapeutic considerations. |
| Q38268827 | Stroke after transcatheter aortic valve replacement: incidence, risk factors, prognosis, and preventive strategies. |
| Q35962795 | Subtle renal dysfunction and bleeding risk in atrial fibrillation: symmetric dimethylarginine predicts HAS-BLED score |
| Q87479910 | Successful resolution of a left ventricular thrombus with apixaban treatment following acute myocardial infarction |
| Q38781617 | Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges |
| Q91158866 | Temporal trends in prevalence and outcomes of atrial fibrillation in patients undergoing percutaneous coronary intervention |
| Q36396649 | The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants |
| Q90429817 | The Management of Combined Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Particularly Complex Challenge, Especially in the Elderly |
| Q37328158 | The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: An open-label, controlled, sequential study. |
| Q92723640 | The efficacy and safety of Shenzhu Guanxin Recipe Granules for the treatment of patients with coronary artery disease: protocol for a double-blind, randomized controlled trial |
| Q38688877 | The future of atrial fibrillation management: integrated care and stratified therapy |
| Q53191924 | The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy. |
| Q92267268 | The myth of 'stable' coronary artery disease |
| Q38247892 | The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties |
| Q47865745 | The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts |
| Q30234909 | The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease |
| Q42180636 | The safety and efficacy of oral anticoagulants with dual versus single antiplatelet therapy in patients after percutaneous coronary intervention: A meta-analysis |
| Q26830164 | The year in atherothrombosis |
| Q47903684 | Thrombo-embolic prevention after transcatheter aortic valve implantation |
| Q64105469 | Thromboembolic and Bleeding Complications in Transcatheter Aortic Valve Implantation: Insights on Mechanisms, Prophylaxis and Therapy |
| Q50012336 | Thromboembolic and bleeding risk management in elderly patients: a case report. |
| Q38154611 | Ticagrelor for acute coronary syndromes |
| Q50986493 | Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression. |
| Q38557198 | Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? |
| Q94562701 | Ticagrelor: A safe option as part of triple therapy? |
| Q52583885 | Time trends in antithrombotic management of patients with atrial fibrillation treated with coronary stents: Results from TALENT-AF (The internAtionaL stENT - Atrial Fibrillation study) multicenter registry. |
| Q54138570 | To neither bleed nor clot: That is the question. |
| Q91873263 | Towards appropriate polypharmacy in older cardiovascular patients: How many medications do I have to take? |
| Q26866350 | Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy |
| Q49990585 | Treatment of gastrointestinal bleeding with idarucizumab in a patient receiving dabigatran |
| Q92652445 | Trial Sequential Analysis Comparing Bleeding and Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation and Acute Coronary Syndrome on Dual versus Triple Therapy |
| Q50852615 | Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel. |
| Q31001917 | Triple Antithrombotic Therapy after Percutaneous Coronary Intervention (PCI) in Patients with Indication for Oral Anticoagulation: Data from a Single Center Registry |
| Q48039374 | Triple Antithrombotic Therapy and Outcomes in Post-PCI Patients Undergoing Non-cardiac Surgery |
| Q48744990 | Triple Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: a Fading Role |
| Q51805253 | Triple Therapy Versus Dual Antiplatelet Therapy for Patients with Atrial Fibrillation and Acute Coronary Syndromes: A Systematic Literature Review. |
| Q89397561 | Triple Therapy: When, if Ever? |
| Q42216679 | Triple antithrombotic therapy for atrial fibrillation and coronary stents |
| Q41011418 | Triple antithrombotic therapy in patients undergoing percutaneous coronary intervention: balancing between ischemia and bleeding |
| Q39193524 | Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a viewpoint |
| Q38123126 | Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting. |
| Q60301382 | Triple therapy after PCI - Warfarin treatment quality and bleeding risk |
| Q38543313 | Triple therapy for percutaneous coronary intervention in atrial fibrillation: standard of care, or a nightmare soon to end? |
| Q90644485 | Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting |
| Q42360039 | Triple troubles selecting optimal therapy for atrial fibrillation patients undergoing percutaneous coronary interventions |
| Q49982021 | Trithérapie antithrombotique pour la fibrillation auriculaire et les endoprothèses coronariennes |
| Q39135634 | Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban |
| Q90529438 | Update on Antithrombotic Therapy after Percutaneous Coronary Intervention |
| Q38556885 | Update on antithrombotic therapy after percutaneous coronary revascularisation |
| Q47789803 | Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism |
| Q97421102 | Updated overview of evidence on optimal antithrombotic therapy in patients with atrial fibrillation undergoing percutanous coronary intervention |
| Q37536810 | Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry |
| Q35542784 | Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry |
| Q37434813 | Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention |
| Q45975657 | Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. |
| Q38496232 | Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice |
| Q57818803 | Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation |
| Q60949999 | Use of direct oral anticoagulants in the treatment of left ventricular thrombi: A tertiary center experience and review of the literature |
| Q90018927 | Use of oral anticoagulants in complex clinical situations with atrial fibrillation |
| Q38941684 | Use of rivaroxaban in patients with stroke |
| Q55364273 | Vasodilator-stimulated phosphoprotein-guided Clopidogrel maintenance therapy reduces cardiovascular events in atrial fibrillation patients requiring anticoagulation therapy and scheduled for percutaneous coronary intervention: a prospective cohort s |
| Q47884992 | Vessel tree tracking in angiographic sequences |
| Q50793412 | Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents. |
| Q91759926 | Vitamin K antagonist vs direct oral anticoagulants with antiplatelet therapy in dual or triple therapy after percutaneous coronary intervention or acute coronary syndrome in atrial fibrillation: Meta-analysis of randomized controlled trials |
| Q86892134 | Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation |
| Q90397785 | When to withhold oral anticoagulation in atrial fibrillation - an overview of frequent clinical discussion topics |
| Q87479971 | [Antiplatelet therapy and anticoagulation in acute coronary syndrome: current evidence] |
| Q85841188 | [Antithrombotic therapy and atrial fibrillation. Dual or triple therapy after acute coronary syndrome and stent?] |
| Q86643067 | [ESC guidelines 2015. Non-ST-elevation acute coronary syndrome] |
| Q51276277 | [Knowledge of guidelines for anticoagulation management of patients with atrial fibrillation]. |
| Q50875552 | [Management of acute coronary syndrome without ST-segment elevation]. |
| Q86039476 | [Management of acute myocardial infarction with ST-segment elevation: Update 2013] |
| Q87307668 | [Medicinal treatment of atrial fibrillation in special situations] |
| Q53535820 | [Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine]. |
| Q89623293 | [Platelet inhibition in elderly patients] |
Search more.